DMS 273

Description

DMS 273 is a human small cell lung carcinoma cell line derived in 1978 from the pleural fluid of a 50-year-old Caucasian female patient who had relapsed following chemotherapy and radiotherapy. Originating from small cell carcinoma of the lung, the cells exhibit an adherent morphology with intercellular processes and retain features of small cell carcinoma. DMS 273 cells are cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C and 5% CO₂. They express mRNA and proteins associated with the retinoblastoma gene and harbor a p53 gene mutation (G245C). Additionally, they express hepatocyte growth factor (HGF) and its receptor, receptor tyrosine kinase MET (RTK-MET). These cells are tumorigenic when implanted in nude mice.

Application

• DMS-273 is a valuable cell line for studying small-cell lung cancer (SCLC), an aggressive cancer known for its high metastatic potential. Transplanting DMS-273 into the lungs of nude mice creates a metastasis model and facilitates the testing of drugs or inhibitors. For instance, DMS-273 exhibits amplification of the SETDB1 gene, resulting in the overexpression of SETDB1 protein, enhancing cell invasion in lung carcinoma. This finding provides insights into the potential application of SETDB1 inhibitors as new therapies. Similarly, in DMS-273, inhibitors or siRNA targeting signaling pathways associated with cancer progression and invasion can be tested to impede the progression of SCLC.